Suzanne Trudel

6PUBLICATIONS
35CO-AUTHORS
Haematological tumoursGene and molecular therapyMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jul 22, 2026
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial.

|Mar 11, 2026
Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.

Rintu Sharma, Andree-Anne Pelland, Katherine Lajkosz

|Jan 04, 2024
Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.

Suzanne Trudel, Arleigh McCurdy, Martha L Louzada

|Oct 02, 2023
Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial.

Nizar J Bahlis, Caitlin L Costello, Noopur S Raje

|Jan 13, 2023
Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.

Danielle C Croucher, Anup Joseph Devasia, Dor D Abelman

|Nov 04, 2021
Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression.

Danielle C Croucher, Laura M Richards, Serges P Tsofack

Pageof 1

Frequent Collaborators

2 joint publications

Danielle C Croucher

2 joint publications

Trevor J Pugh

2 joint publications

Alexander M Lesokhin

2 joint publications

Nizar J Bahlis